Health officials from Northeast Ohio are intensifying their calls for people to explore recently approved vaccines against the seasonal respiratory syncytial virus (RSV). Over the past few months, several RSV vaccines have secured approval from the Food and Drug Administration (FDA), with a specific focus on safeguarding infants and elderly individuals. Erin Murphy, who oversees health promotion and chronic disease prevention at Lorain County Public Health, highlighted the severity of RSV among these demographic groups.
RSV often presents mild, cold-like symptoms in most individuals. However, the virus can impose a severe health impact on older adults, infants, and young children. To mitigate this risk, the FDA has embarked on a series of vaccine approvals aimed at high-risk groups.
One such vaccine is Abrysvo, which gained approval on August 21, marking the first RSV vaccination approved for administration in pregnant individuals. This vaccine seeks to prevent lower respiratory tract disease and severe lower respiratory infections in infants from birth through 6 months. Importantly, Abrysvo is also approved for use during the 32 to 36 weeks gestation period.
This approval trails the July clearance of Beyfortus, another RSV vaccine designed to protect infants up to 24 months. Moreover, the FDA approved Arexvy in May, extending protection to patients aged 60 and older.
Data from the Centers for Disease Control reveals that the overall RSV-related hospitalizations rate during the 2022-23 RSV season stood at 50.8 per 100,000 individuals. A surge in cases was notable in Ohio from October to December, with the highest concentration in mid- to late-November. The highest incidence rates occurred in the 0-4 age group and amongst those 65 and older.
Dr. Claudia Hoyen, director of pediatric infection control at University Hospitals Rainbow Babies and Children’s Hospital, indicated that 600,000 U.S children end up in the doctor’s office or local hospitals for RSV treatment annually. She expressed that widespread RSV vaccinations could help to alleviate the burden placed on the healthcare system during the winter illness period. Hoyen referred to the 2022 ‘tripledemic’ that exerted significant pressure on the healthcare system with a surge of COVID-19, RSV, and flu cases.
Agreeing with Hoyen’s sentiments, Murphy underscored that such vaccines offer an additional tool in the arsenal against seasonal respiratory ailments, particularly critical during current public health crises. These vaccines, she said, are critical for keeping people protected and curtailing the spread of these diseases.
Source: https://www.ideastream.org/health/2023-09-05/health-officials-urge-use-of-new-rsv-vaccine-to-protect-vulnerable-populations